An Illumina press-release:
deCODE Receives Illumina CSPro(TM) Certification for Delivering Top Quality SNP Genotyping Services

SAN DIEGO, Feb 14, 2007 (BUSINESS WIRE) -- Illumina (NASDAQ:ILMN) announced today that deCODE genetics, which operates the world's largest services facility offering Illumina single-nucleotide polymorphisms (SNP) genotyping services, has received Illumina Certified Service Provider (CSPro) certification for Infinium(R) Genotyping.
Illumina, a San Diego-based company, provides next-generation tools for the large-scale analysis of genetic variation and function. deCODE, a global leader in applying human genetics to develop better medicine, has partnered with Illumina to provide unique, high-value content for the Infinium Genotyping BeadChip, delivering industry-leading results for genotyping service customers.

"We chose Illumina because their data quality is the best in the industry, and through our genotyping services we can in turn offer this level of quality to our customers around the world. Our Disease Miner(TM) informatics suite further provides our customers with a user-friendly means of performing their own data management and statistical analyses," said Jeff Gulcher, deCODE's Chief Scientific Officer. "Receiving CSPro certification underscores deCODE's commitment to providing the best and most comprehensive genotyping and analytical solutions, speeding the discovery process for our customers."

"deCODE is the largest laboratory to offer Infinium Genotyping services, serving a growing list of customers in North America, Europe, and Asia. They are also the first laboratory outside of North America to achieve Illumina CSPro certification for Infinium Genotyping," said Karen Possemato, Illumina's Director of Corporate Marketing. "By contributing its unrivalled expertise in human genetics, deCODE has helped to ensure that next generation Infinium Genotyping products lead the industry in quality and content."

About Illumina CSPro

Illumina CSPro is a collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPros undergo a rigorous two-phase certification process that includes minimum data generation requirements, data certification and on-site audit of the facility and processes. For more information about the CSPro program, please visit www.illumina.com/cspro.

About Illumina

Illumina (www.illumina.com) is developing next-generation tools for the large-scale analysis of genetic variation and function.

About deCODE Genotyping Services

deCODE operates the largest and most advanced high-throughput genotyping facility in the world, supported by its renowned scientists in genetics, robotics, statistics, and informatics. The company has extensive experience in providing genotyping services and has developed powerful software tools to help its customers speed the discovery process. deCODE provides a full range of services, including Infinium platform SNP genotyping, with a capacity of 3 billion SNPs per month; microsatellite genotyping for genome-wide scans and fine-mapping; and DNA sample preparation. For more information, please visit our website at www.decode.com/genotyping.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation with Affymetrix, our ability to effectively integrate our recent acquisition of Solexa, Inc., Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, Illumina's ability to manufacture robust Sentrix(R) arrays and Oligator(R) oligonucleotides, Illumina's ability to scale and integrate CyVera technology, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

SOURCE: Illumina

Illumina, Inc.
Maurissa Bornstein, 858-332-4055
Public Relations Manager
mbornstein@illumina.com

or

deCODE genetics
Pernille Sorensen Baker, Ph.D., 354-570-2807
Director of Marketing, Genotyping Services
genotyping@decode.com